Clinical trials: Acute Myelocytic Leukemia
Multiple Myeloma, Acute Myeloid Leukemia
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT04543305
- Testing
- PRT1419
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Prelude Therapeutics Incorporated
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
By doing this study, researchers hope to learn the following: If providing hyperbaric oxygen (HBO) therapy prior to an umbilical cord blood (UBC) transplant will help to improve the homing process The safety of HBO administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Hodgkins Lymphoma
- Trial name
- NCT02099266
- Testing
- Administration of hyperbaric oxygen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Kansas Medical Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
The purpose of this study is to evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units meeting a predetermined total minimum cell dose of 2.0 x 10 to the seventh total nucleated cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT00328237
- Testing
- Cord Blood Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma
- Trial name
- MITCL (NCT01842672)
- Testing
- Clofarabine, Mitoxantrone
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- New York Medical College
Myelodysplastic Syndrome, Acute Myeloid Leukemia
GVAX vs. Placebo for MDS/AML After Allo HSCT
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether the intervention, in this case, the GVAX vaccine, works in preventing MDS…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01773395
- Testing
- GVAX, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan
- Where
- 4 sites in United States
- Volunteers
- 123 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
The study aims to detect pattern of expression of PHF19 gene and EZH2 gene deletion in acute myeloid leukemia patients and detect their prognostic role on patients outcome.
- Trial name
- NCT04215822
- Testing
- Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
- Volunteers
- 80 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia, Myelodysplasia
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS
Relapse after an allogeneic hematopoietic stem cell transplantation (HSCT) is high in patients with advanced AML, in the 50% range.
- Trial name
- Bigeminy (NCT04166929)
- Testing
- Haplo SCT with NK cells, Haplo SCT
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Leukemia, Myeloid, Acute
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
- Trial name
- NCT01390337
- Testing
- AC220, daunorubicin, cytarabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.
- Trial name
- NCT01433965
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Davis
AML, IDH1 Mutation
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Venetoclax can bind to the BCL-2 protein, thereby initiating the apoptosis program and exerting anti-AML effects. The induction regimen combining venetoclax with hypomethylating agents (HMA) significantly improves the remission…
- Conditions
- AML, IDH1 Mutation, Treatment
- Trial name
- IDH1-AML-2024 (NCT06611839)
- Testing
- Ivosidenib, Venetoclax, Azacitidine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Lymphoma
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies.
- Trial name
- NCT00038857
- Testing
- Megadose of CD34 Selected Progenitor Cells, Melphalan, Thiotepa
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML)
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body…
- Trial name
- NCT00363467
- Testing
- G-CSF, Leukapheresis, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
This clinical trial studies potential genetic markers which might be used to predict which patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine.
- Trial name
- NCT01687400
- Testing
- decitabine
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
The purpose of this study is to find out how safe and effective the combination of Mylotarg in combination with cytarabine is in treating patients with Acute Myeloid Leukemia and advanced Myelodysplastic Syndrome over the age of…
- Trial name
- NCT00195000
- Testing
- Mylotarg, Cytarabine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Weill Medical College of Cornell University
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
The hypothesis of this study is that 5-aza and lenalidomide act synergistically in MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q.
- Trial name
- AZALE (NCT00923234)
- Testing
- Azacitidine, Lenalidomide
- Where
- 4 sites in Germany
- Sponsor
- Technische Universität Dresden
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
This phase II trial studies how well 3 different drug combinations prevent graft versus host disease (GVHD) after donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03602898
- Testing
- Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Acute
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study.
- Trial name
- NCT03988205
- Testing
- Outpatient Care Model, CPX-351
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.
- Conditions
- Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM), T-Cell Leukemia/Lymphoma, Adult
- Trial name
- NCT05513612
- Testing
- Autologous CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Sponsor
- Shanghai Pudong Hospital
Acute Myeloid Leukemia
Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia
This pilot study will use a mixed methods approach to evaluate the feasibility and acceptability of Integrative Therapies, a bedside service offering mindfulness-based interventions (still meditation, meditative movement…
- Trial name
- NCT04185428
- Testing
- Integrative Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Florida